Carnitine Profile Changes in Pediatric Hematopoietic Stem Cell Transplant: New Role for Carnitine?. Issue 5 (July 2020)

• Record Type: Journal Article
• Authors: Law, Susanna F.; Fenton, Tanis R.; Snyder, Floyd F.; Fung, Ernest; Lewis, Victor
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 5(2020)
• Publication Date: 2020-07
• Subjects: carnitine -- stem cell transplant -- graft-versus-host disease -- mortality -- chemotherapy; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001723
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Carnitine is an essential cofactor for mitochondrial import and oxidation of fatty acids. High-dose chemotherapy and radiation, often required for hematopoietic stem cell transplant (HSCT), leads to tissue damage, mitochondrial dysfunction, and alterations in carnitine metabolism. The aim of this pilot cohort study was to describe plasma and urinary carnitine profiles during pediatric HSCT and their relationships with clinical outcomes. Plasma and urinary carnitine samples were collected from 22 pediatric patients before and through day 180 post-HSCT. Associations were observed between graft-versus-host disease and an elevated plasma total carnitine ( P =0.019), and also increased plasma acyl:free carnitine ratio with veno-occlusive disease ( P =0.016). Mortality was observed in those with their highest urinary total carnitine losses on day 0 ( P =0.005), and in those with an abnormal day 28 plasma ratio either above or below the reference range ( P =0.007). Changes in carnitine profiles were more reflective of metabolic stress and negative outcomes than of inadequate dietary intake. Associations observed direct larger studies to assess the validity of carnitine profiles as a prognostic indicator and also to assess whether prophylactic carnitine supplementation pre-HSCT could reduce mitochondrial injury and urinary losses and help mitigate inflammatory and metabolic comorbidities of HSCT.